Search results for " Embolism"

showing 10 items of 311 documents

Thrombosis

2014

Background— Thrombosis is the common pathology underlying ischemic heart disease, ischemic stroke, and venous thromboembolism (VTE). The Global Burden of Disease Study 2010 (GBD 2010) documented that ischemic heart disease and stroke collectively caused 1 in 4 deaths worldwide. GBD 2010 did not report data for VTE as a cause of death and disability. Objective— To review the literature on the global burden of disease caused by VTE. Approach and Results— We performed a systematic review of the literature on the global disease burden because of VTE in low-, middle-, and high-income countries. Studies from Western Europe, North America, Australia, and Southern Latin America (Argentina) yielded…

medicine.medical_specialtyPopulation ageingPopulationMyocardial IschemiaDisease030204 cardiovascular system & hematologyGlobal HealthCohort Studies03 medical and health sciencesLife Expectancy0302 clinical medicineCost of IllnessCause of DeathEnvironmental healthGlobal healthPrevalenceHumansMedicinecardiovascular diseases030212 general & internal medicineIntensive care medicineeducationStrokeDisease burdenCause of deathVenous Thrombosiseducation.field_of_studybusiness.industryIncidenceIncidence (epidemiology)Racial GroupsAge FactorsThrombosisVenous ThromboembolismHematologymedicine.diseaseThrombosis3. Good healthStrokePneumoniaVenous thrombosisSocial ClassQuality-Adjusted Life YearsMedical emergencyPulmonary EmbolismCardiology and Cardiovascular MedicinebusinessArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Edoxaban for pulmonary embolism with right ventricular dysfunction

2016

medicine.medical_specialtyPyridinesbusiness.industryVentricular Dysfunction RightVenous ThromboembolismHematology030204 cardiovascular system & hematologymedicine.diseaseRight ventricular dysfunctionPulmonary embolismThiazoles03 medical and health scienceschemistry.chemical_compound0302 clinical medicineText miningchemistryEdoxabanInternal medicinemedicineCardiologyHumans030212 general & internal medicinePulmonary EmbolismbusinessThe Lancet Haematology
researchProduct

Cardiac arrest in special circumstances

2021

Purpose of review European Resuscitation Council Guidelines for Cardiopulmonary Resuscitation prioritize treatments like chest compression and defibrillation, known to be highly effective for cardiac arrest from cardiac origin. This review highlights the need to modify this approach in special circumstances. Recent findings Potentially reversible causes of cardiac arrest are clustered into four Hs and four Ts (Hypoxia, Hypovolaemia, Hyperkalaemia/other electrolyte disorders, Hypothermia, Thrombosis, Tamponade, Tension pneumothorax, Toxic agents). Point-of-care ultrasound has its role in identification of the cause and targeting treatment. Time-critical interventions may even prevent cardiac…

medicine.medical_specialtyResuscitationDefibrillationbusiness.industrymedicine.medical_treatmentWater-Electrolyte ImbalanceHypothermiaHypothermiaReturn of spontaneous circulationCritical Care and Intensive Care Medicinemedicine.diseaseThrombosisCardiopulmonary ResuscitationHeart ArrestPulmonary embolismPregnancymedicineHumansFemaleTamponadeCardiopulmonary resuscitationmedicine.symptomIntensive care medicinebusinessOut-of-Hospital Cardiac ArrestCurrent Opinion in Critical Care
researchProduct

European Resuscitation Council Guidelines 2021: Cardiac arrest in special circumstances

2021

These European Resuscitation Council (ERC) Cardiac Arrest in Special Circumstances guidelines are based on the 2020 International Consensus on Cardiopulmonary Resuscitation Science with Treatment Recommendations. This section provides guidelines on the modifications required to basic and advanced life support for the prevention and treatment of cardiac arrest in special circumstances; specifically special causes (hypoxia, trauma, anaphylaxis, sepsis, hypo/hyperkalaemia and other electrolyte disorders, hypothermia, avalanche, hyperthermia and malignant hyperthermia, pulmonary embolism, coronary thrombosis, cardiac tamponade, tension pneumothorax, toxic agents), special settings (operating ro…

medicine.medical_specialtyResuscitationbusiness.industrymedicine.medical_treatment030208 emergency & critical care medicine030204 cardiovascular system & hematologyEmergency NursingHypothermiamedicine.diseasePulmonary embolismCardiac surgeryAdvanced life support03 medical and health sciencesMass-casualty incident0302 clinical medicineCardiac tamponadeEmergency MedicinemedicineCardiopulmonary resuscitationmedicine.symptomCardiology and Cardiovascular MedicineIntensive care medicinebusinessResuscitation
researchProduct

Response to ‘Detecting right ventricular dysfunction in patients diagnosed with low-risk pulmonary embolism: is routine computed tomographic pulmonar…

2019

medicine.medical_specialtyRivaroxabanmedicine.diagnostic_testmedicine.drug_mechanism_of_actionbusiness.industryFactor Xa Inhibitormedicine.diseaseRight ventricular dysfunctionPulmonary embolismComputed tomographicAngiographyPulmonary angiographyMedicineIn patientRadiologyCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal
researchProduct

Use of bivalirudin for heparin-induced thrombocytopaenia after thrombolysis in massive pulmonary embolism: a case report

2009

A 68-year-old man was referred to the emergency department 6 h after onset of sudden acute dyspnoea. Immediate ECG showed sinus tachycardia with the typical S1-Q3-T3 pattern and incomplete right bundle branch block. The echocardiogram showed the presence of mobile thrombus in the right atrium, a distended right ventricle with free wall hypokinesia and displacement of the interventricular septum towards the left ventricle. Lung spiral computed tomography (CT) showed bilateral pulmonary involvement and confirmed the picture of a thrombotic system in the right atrium and caval vein. Thrombolytic treatment with recombinant tissue plasminogen activator (rt-PA) and heparin (alteplase 10 mg bolus,…

medicine.medical_specialtySettore MED/09 - Medicina Internamedicine.medical_treatmentCase ReportInternal medicinebivalirudin Heparin-induced thrombocytopaenia Pulmonary embolism ThrombolysismedicineBivalirudinHeparin-induced thrombocytopaeniaInterventricular septumcardiovascular diseasesThrombusLungbusiness.industryPulmonary embolismThrombolysismedicine.diseaseThrombolysisSpiral computed tomographyPulmonary embolismmedicine.anatomical_structureVentricleCardiologycardiovascular systemEmergency MedicinebusinessBivalirudinmedicine.drugInternational Journal of Emergency Medicine
researchProduct

Consideraciones preoperatorias y manejo neuroanestesiológico intraoperatorio

2012

The anesthesiological management of patients undergoing neurosurgery of the posterior fossa has a series of characteristics that should be known by anesthesiologists. Intraoperative management is guided by a series of factors that include the physiopathological changes secondary to the patient's position during surgery, the importance of appropriate patient positioning to facilitate the surgical approach, the lower tolerance to changes in the elastance of the infratentorial region, the limited therapeutic options in episodes of intraoperative edema-swelling, and the presence of complications such as a venous air embolism. This first contribution to the guidelines discusses the main evidence…

medicine.medical_specialtySurgical approachInfratentorial regionbusiness.industryPosterior fossaPatient positioningVenous air embolismCritical Care and Intensive Care MedicineElastanceSurgeryAnesthesiology and Pain MedicineIntraoperative managementmedicineNeurosurgerybusinessRevista Española de Anestesiología y Reanimación
researchProduct

D-dimer testing: advantages and limitations in emergency medicine for managing acute venous thromboembolism

2007

Patients with suspected deep vein thrombosis (DVT) or pulmonary embolism (PE) are frequently admitted to an Emergency Department (ED) for initial evaluation. However, management of patients with suspicion of acute venous thromboembolism (VTE) in this clinical setting can be difficult; in fact symptoms and signs of DVT are non-specific and can be found in a broad spectrum of non-thrombotic disorders. An accurate and timely objective diagnosis is necessary for immediate and correct identification of patients with acute VTE, while avoiding the bleeding risk associated with unnecessary anticoagulant therapy in patients where DVT or PE have been ruled out. The diagnostic approach to patients wit…

medicine.medical_specialtyTime FactorsMEDLINEEnzyme-Linked Immunosorbent AssayEnglish languageDiseaseSensitivity and SpecificityFibrin Fibrinogen Degradation ProductsNephelometry and TurbidimetryD-dimermedicineInternal MedicineHumanscardiovascular diseasesProspective cohort studyLetters to the EditorIntensive care medicinePathologicalVenous ThrombosisPregnancybusiness.industryClinical judgementData synthesisEmergency departmentmedicine.diseasePulmonary embolismD-dimer emergency medicine venous thromboembolismVenous thrombosisAcute DiseaseEmergency medicineEmergency MedicineEmergenciesbusinessVenous thromboembolismAlgorithmsBlood samplingInternal and Emergency Medicine
researchProduct

Home treatment of pulmonary embolism: are all the questions answered now after the HOME-PE trial?

2020

medicine.medical_specialtyTime FactorsPhysiologyClinical Decision-MakingRisk AssessmentSeverity of Illness IndexDecision Support TechniquesPredictive Value of TestsRisk FactorsPhysiology (medical)medicineHumansIntensive care medicineLungbusiness.industryLength of StayPrognosismedicine.diseaseHome Care ServicesThrombosisPatient DischargePulmonary embolismmedicine.anatomical_structureHome treatmentPulmonary EmbolismCardiology and Cardiovascular MedicinebusinessCardiovascular Research
researchProduct

A new thrombectomy catheter device (AngioJet) for the disruption of thrombi: An in vitro study

1999

In this study we examined a new thrombectomy catheter device. Different kinds of in vitro generated thrombi and cadaver thrombi were disrupted in test tubes. The mean disruption rate (and disruption time for 1 g of thrombus) was 225 +/- 65 mg/sec (5 +/- 2 sec) for whole-blood, 117 +/- 60 mg/sec (12 +/- 9 sec) for fibrin, 41 +/- 18 mg/sec (30 +/- 18 sec) for mixed, 70 +/- 42 mg/sec (17 +/- 5 sec) for unorganized, 45 +/- 8 mg/sec (22 +/- 4 sec) for partly, and 5 +/- 1 mg/sec (216 +/- 29 sec) for completely organized cadaver thrombi (P0.05). More than 99% of fragmented particles of whole-blood thrombi were 0-12 microm in diameter. The particle size of fibrin, mixed, and cadaver thrombi was sim…

medicine.medical_specialtyTime Factorsmedicine.medical_treatmentIn Vitro TechniquesFibrinCatheterizationCadavermedicineHumansRadiology Nuclear Medicine and imagingParticle SizeThrombusThrombectomybiologybusiness.industryCatheter deviceThrombosisEquipment DesignGeneral MedicineThrombolysismedicine.diseaseThrombosisPulmonary embolismSurgerymedicine.anatomical_structureEmbolismbiology.proteinPulmonary EmbolismCardiology and Cardiovascular MedicineNuclear medicinebusinessArteryCatheterization and Cardiovascular Interventions
researchProduct